The roles of BRCA1 and BRCA2 mutations in chemosensitizing ovarian cancer and improving prognosis are well known [74, 75], as are the mechanisms by which these can be reversed in development of chemoresistance [73]. This evidence concerns the gene BRCA2 and ovarian cancer.